Latest Conference Articles

Navigating Treatment Options for Patients With Early-Stage Breast Cancer

Genetic advances have helped elucidate the heterogenous nature of breast cancer, however optimal strategies for patients with early-stage disease still need to be ironed out.

Survivorship Starts at Diagnosis in Breast Cancer

The inclusion of patients from the time of diagnosis and encompassing family, friends, and caregivers is central to moving survivorship care forward, especially for breast cancer survivorship, which has high survival rates for early disease and the emergence of novel treatments for advanced cancers.

Dr. O'Shaughnessy on the Utility of Capivasertib in Targeting Akt in Breast Cancer

Joyce A. O'Shaughnessy, MD, discusses the utility of targeting capivasertib in targeting Akt mutations in breast cancer.

Dr. Tripathy on Personalized Therapy Options in Metastatic Breast Cancer

Debu Tripathy, MD, discusses personalized therapy options in metastatic breast cancer.

Gottlieb Addresses Coronavirus, Innovation in Keynote Address

The novel coronavirus spreading across the world represents a distinct challenge for all physicians, especially oncologists who commonly treat patients who have compromised immune systems.

Exercise Programs Improve Outcomes for Patients With Breast Cancer

Special attention to reducing the risk of cardiovascular disease should be a priority for long-term care of patients with breast cancer.

Dr. Borgen on the De-Escalation of Surgery in Breast Cancer

Patrick I. Borgen, MD, discusses the trend toward surgical de-escalation in patients with breast cancer.

Dr. Soto Perez de Celis on Nuances of Treating Older Patients With Breast Cancer

Enrique Soto Pérez de Celis, MD, MSc, discusses nuances of treating older patients with breast cancer.

Novel Antibody-Drug Conjugates Show Encouraging Activity in TNBC

Novel antibody-drug conjugates have demonstrated high response rates in patients with heavily pretreated metastatic breast cancer, and ongoing studies targeting actionable cell-surface markers may further expand their clinical utility, according to Aditya Bardia, MD, MPH.

Rugo Spotlights Potential With Tucatinib, Other Novel Agents in HER2+ Breast Cancer

Hope S. Rugo, MD, discusses the pending approval of tucatinib in metastatic HER2-positive breast cancer and other potentially practice-changing agents in the pipeline.

All Stakeholders Are Responsible for Genetic Testing

Physicians should “get out there and test early and often,” to align with a potential new paradigm for genetic testing that allows anyone on the treatment team to identify and test individuals, with the specialist ultimately providing risk management, according to Kevin S. Hughes, MD, FACS.

Immunotherapy Comes of Age in Breast Cancer

Breast cancer has historically been an immunologically cold disease, but recent and emerging data are carving out a space for several immunotherapies in the treatment paradigm.

Dr. Hughes on Genetic Testing in Breast Cancer

Kevin Hughes, MD, discusses the role of genetic testing in breast cancer.

Gene Profiling Essential Tool for Treatment Tailoring

Gene profiling assays can accurately and reproducibly assist decision making for patients with hormone receptor-positive breast cancer, with the ultimate goal of improving outcomes or avoiding toxicity.

Dr. Robson on the Potential Utility of Tucatinib in HER2+ Breast Cancer

Mark E. Robson, MD, discusses the potential utility of tucatinib in the treatment of patients with HER2-positive breast cancer.

CDK4/6 Inhibitors Reach New Benchmarks in Overall Survival in HR+ Breast Cancer

The release of new evidence that CDK4/6 inhibition results in survival gains for patients with hormone receptor–positive, HER2-negative metastatic breast cancer marks a new milestone for the therapeutic approach and may help set the stage for expanding use of these agents into earlier clinical settings.

Can We Use Genomic Profiling Data to Influence Locoregional Treatment Decisions in Breast Cancer?

Given the solid correlation between the risk of locoregional recurrence (LRR) and distant recurrence, several investigators have examined whether genomic assays that predict risk of distant recurrence can also predict risk of LRR.

Biomarkers, Patient Factors Inform HCC Treatment Decisions Beyond Frontline Setting

There are clear biomarkers available to guide treatment decisions in the second-line setting for patients with advanced hepatocellular carcinoma, Lipika Goyal, MD, Mphil, said during a presentation at the 2020 HCC-TAG Conference.

El-Khoueiry Forecasts Future of HCC Treatment Paradigm

By 2025, Anthony El-Khoueiry, MD, expects to see a larger menu of approved drugs and drug combinations for the treatment of advanced hepatocellular carcinoma, better use of molecular and immune signatures to guide treatment decisions, and, possibly, the chance to cure intermediate- and advanced-stage disease.

Recent Approvals, Collaborative Care Model Spark Change in HCC Treatment

Michael R. Charlton, MD, MBBS, discusses the evolution of hepatocellular carcinoma treatment.

Dr. Salem on Locoregional Therapy Versus Systemic Therapy in HCC

Riad Salem, MD, discusses the utility of locoregional therapy versus systemic therapy in the treatment of patients with hepatocellular carcinoma.

Dr. Singal on the Importance of Early Diagnosis in HCC

Amit G. Singal, MD, discusses the importance of early diagnosis for patients with hepatocellular carcinoma.

Pivotal Studies Provide New Path in High-Risk Smoldering Myeloma

The diagnosis and management of smoldering multiple myeloma is an area of tremendous focused research and change over the past decade, with trials yielding intriguing findings that have the potential to change practice.

Immunotherapy Combinations Show Promise in Advanced HCC

Following a series of negative phase III single-agent trials in hepatocellular carcinoma, investigators are finding better results with immunotherapy combination regimens.

Evidence Illustrates Multidisciplinary Care Is Standard in HCC

Clinical evidence shows that patients with hepatocellular carcinoma who receive care that incorporates multiple providers from a variety disciplines leads to better results.

Pillai Reflects on Achieved Goals at Inaugural HCC-TAG Conference

Anjana Pillai, MD, reflects on the first annual HCC-TAG Conference, her journey into treating patients with liver cancer, and remaining challenges in the paradigm

Next Chapter Begins With CAR T-Cell Therapy in Myeloma

Noopur Raje, MD, discusses the investigational CAR T-cell therapies and strategies in the multiple myeloma pipeline.

Unmet Needs Remain in GVHD, But Novel Approaches on Horizon

Corey S. Cutler, MD, MPH, discusses how physicians can optimize treatment management in patients with both acute and chronic graft-versus-host-disease.

Dr. Radich on the Evolving Role of MRD in Hematologic Malignancies

Jerald P. Radich, MD, discusses how the role of minimal residual disease (MRD) has evolved recently in clinical trials of hematologic malignancies.

Dr. Hoshida on Molecular Subtyping in HCC

Yujin Hoshida, MD, PhD, discusses molecular subtyping in hepatocellular carcinoma.